Prelude climbs as FDA clears study for Incyte-partnered cancer candidate
Source: SeekingAlpha
2026-02-03 11:37:03 ET
More on Prelude Therapeutics, Incyte
- What Investors Should Know Before Buying Incyte
- Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Incyte: Buy For The Turnaround, Stay For The Pipeline
- Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication
- Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy
Read the full article on Seeking Alpha
For further details see:
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate
Prelude Therapeutics Incorporated
NASDAQ: PRLD
PRLD Trading
7.65% G/L:
$3.52 Last:
266,882 Volume:
$2.99 Open:
PRLD Latest News
March 10, 2026 07:01:00 am
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
February 17, 2026 08:24:00 am
The FDA Cleared 50 Oncology Approvals in 2025 and the Pipeline Keeps Accelerating
PRLD Stock Data
$130,131,109
16,400,390
0.33%
16
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmington
